



RECEIVED

1614 #9

MAY 22 2003

TECH CENTER 1600/2900

ATTORNEY DOCKET NO. 50291/002001

Certificate of Mailing: Date of Deposit: May 16, 2003

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Kathy Meuse

Printed name of person mailing correspondence

Kathy Meuse

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Robert Chalifour et al.

Art Unit: 1614

Serial No.: 10/009,122

Examiner: Not yet assigned

Filed: June 18, 2002

Customer No.: 21559

Title: Stereoselective Antifibrillogenic Peptides and Peptidomimetics
ThereofCommissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450REVOCATION AND NEW POWER OF ATTORNEY

Under 37 C.F.R. § 3.73(b), Neurochem, Inc., a corporation, certifies that it is the assignee of 100% of the right, title, and interest in the patent application identified above by virtue of an assignment from the inventors named on the application. A copy of the assignment, which is being recorded in connection with this application today, is enclosed.

The undersigned, whose title is supplied below, is empowered to act on behalf of the assignee.

attorney previously granted in the application and appoints: Paul T. Clark, Reg. No. 30,162; Karen L. Elbing, Ph.D., Reg. No. 35,238; Kristina Bieker-Brady, Ph.D., Reg. No. 39,109; Susan M. Michaud, Ph.D., Reg. No. 42,885; James D. DeCamp, Ph.D., Reg. No. 43,580; Sean J. Edman, Reg. No. 42,506; Vicki L. Healy, Ph.D., Reg. No. 48,343; Jan Tittel, Ph.D., Reg. No. 52,290; J. Cooper McDonald, Ph.D., Reg. No. 52,011; Jeffrey Ellison, Ph.D., Reg. No. 51,649; and Michael J. Belliveau, Ph.D., Reg. No. 52,608 with full power of substitution and revocation, to prosecute the application and to transact all business in the United States Patent and Trademark Office connected therewith.


All correspondence regarding the application should now be sent to:

Karen L. Elbing, Ph.D.
Clark & Elbing LLP
101 Federal Street
Boston, MA 02110

Telephone: 617-428-0200
Facsimile: 617-428-7045
Customer No.: 21559

Date: 31/03/2003

Respectfully submitted,



Claude Michaud
Senior Vice President, Finance & Chief
Financial Officer
Neurochem, Inc.



COPY**ASSIGNMENT**

For valuable consideration, we,

Full Name of Assignor	Address
Robert Chalifour	332 Place Ladouceur, Ile Bizard, Québec H9C 1T4 Canada
Francine Gervais	1003 Bellevue, Ile Bizard, Québec H9C 2X5 Canada
Ajay Gupta	255 St. Louis, Pointe Claire, Québec H9R 5L6 Canada

hereby assign to

Full Name of Assignee	Business Address
Neurochem Inc.	7220, rue Frederick-Banting, Bureau 100, Ville Saint Laurent, Québec, Canada, H4S 2A1

and to its successors and assigns (collectively hereinafter called "the Assignee"), the entire right, title, and interest throughout the world in the inventions and improvements which are subject of one or more patent applications identified as:

Title of Application	Filing Date	Serial Number
Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof	May 5, 1999	U.S. Serial No. 60/132,592
Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof	May 4, 2000	PCT/CA00/00515
Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof	June 18, 2002	U.S. Serial No. 10/009,122
Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof	May 4, 2000	Australian Application No. 45298/00
Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof	May 4, 2000	Canadian Application No. 2,388,092
Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof	May 4, 2000	European Patent Application No. 00926599.2
Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof	May 4, 2000	Hong Kong application corresponding to European Patent Application No. 00926599.2
Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof	May 4, 2000	Israel Application No. 146009

Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof	May 4, 2000	Japanese Application No. 2000-616237
Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof	May 4, 2000	New Zealand Application No. 515807

This assignment includes said applications, any and all patent applications (including continuation applications, divisional applications, continuation-in-part applications, and reissue applications), patents, reissues, extensions, utility models, and design registrations granted for any of said inventions or improvements, in any country, and the right to claim priority based on the filing date of said application under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and we authorize the Assignee to apply in all countries in our names or in its own name for patents, utility models, design registrations, and like rights of exclusion, and for inventors' certificates for said inventions and improvements; and we agree for ourselves and our respective heirs, legal representatives and assigns, without further compensation, to perform such lawful acts and to sign such further applications, assignments, Preliminary Statements, and other lawful documents as the Assignee may reasonably request to effectuate fully this assignment. This assignment is effective as of the filing dates of each of the listed applications.

IN WITNESS WHEREOF, I hereto set my hand and seal at _____,
this ____ day of _____, 20__.

Robert Chalifour L.S.

Witness #1: _____
signature printed name date

Witness #2: _____
signature printed name date

IN WITNESS WHEREOF, I hereto set my hand and seal at _____,
this ____ day of _____, 20__.

Francine Gervais L.S.

Witness #1: _____
signature printed name date

Witness #2: _____
signature printed name date

IN WITNESS WHEREOF, I hereto set my hand and seal at Montreal, Quebec,
this 11th day of April, 2003

Ajaya
Ajay Gupta L.S.

Witness #1: [Signature] LEONTII TERYAKOV April 11, 2003
signature printed name date

Witness #2: [Signature] MICHAEL VOULERS April 11, 2003
signature printed name date

ASSIGNMENT**COPY**

For valuable consideration, we,

Full Name of Assignor	Address
Robert Chalifour	332 Place Ladouceur, Ile Bizard, Québec H9C 1T4 Canada
Francine Gervais	1003 Bellevue, Ile Bizard, Québec H9C 2X5 Canada
Ajay Gupta	255 St. Louis, Pointe Claire, Québec H9R 5L6 Canada

hereby assign to

Full Name of Assignee	Business Address
Neurochem Inc.	7220, rue Frederick-Banting, Bureau 100, Ville Saint Laurent, Québec, Canada, H4S 2A1

and to its successors and assigns (collectively hereinafter called "the Assignee"), the entire right, title, and interest throughout the world in the inventions and improvements which are subject of one or more patent applications identified as:

Title of Application	Filing Date	Serial Number
Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof	May 5, 1999	U.S. Serial No. 60/132,592
Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof	May 4, 2000	PCT/CA00/00515
Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof	June 18, 2002	U.S. Serial No. 10/009,122
Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof	May 4, 2000	Australian Application No. 45298/00
Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof	May 4, 2000	Canadian Application No. 2,388,092
Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof	May 4, 2000	European Patent Application No. 00926599.2
Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof	May 4, 2000	Hong Kong application corresponding to European Patent Application No. 00926599.2
Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof	May 4, 2000	Israel Application No. 146009

Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof	May 4, 2000	Japanese Application No. 2000-616237
Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof	May 4, 2000	New Zealand Application No. 515807

This assignment includes said applications, any and all patent applications (including continuation applications, divisional applications, continuation-in-part applications, and reissue applications), patents, reissues, extensions, utility models, and design registrations granted for any of said inventions or improvements, in any country, and the right to claim priority based on the filing date of said application under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and we authorize the Assignee to apply in all countries in our names or in its own name for patents, utility models, design registrations, and like rights of exclusion, and for inventors' certificates for said inventions and improvements; and we agree for ourselves and our respective heirs, legal representatives and assigns, without further compensation, to perform such lawful acts and to sign such further applications, assignments, Preliminary Statements, and other lawful documents as the Assignee may reasonably request to effectuate fully this assignment. This assignment is effective as of the filing dates of each of the listed applications.

IN WITNESS WHEREOF, I hereto set my hand and seal at Ville Saint Laurent,
this 1st day of April, 2003.

Robert Chalifour L.S.
Robert Chalifour

Witness #1: G. Sebastiani GIOVANNA SEBASTIANI April 1, 2003
signature printed name date

Witness #2: Richard McLaughlin Richard McLaughlin April 1, 2003
signature printed name date

IN WITNESS WHEREOF, I hereto set my hand and seal at DORVAL,
this 31 day of MARCH, 2003.

Francine Gervais L.S.
Francine Gervais

Witness #1: Line Pelosse LINE PELOSSE 31-03-2003
signature printed name date

Witness #2: Denis Garceau DENIS GARCEAU 31-03-03
signature printed name date

IN WITNESS WHEREOF, I hereto set my hand and seal at _____,
this ____ day of _____, 20__.

Ajay Gupta L.S.

Witness #1: _____
signature printed name date

Witness #2: _____
signature printed name date